Arvinas (ARVN)

• Market cap: $568M
• 1 day: -1.29%
• 5 days: -4.02%
• 1 month: 6.56%
• 3 months: 3.66%
• 6 months: -12.18%
• Year to date: -59.56%
• 1 year: -69.62%
• 5 years: -72.07%
• 10 years: -52.4%
• Sector: Healthcare
• Industry: Biotechnology

About: Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Employees: 430

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

296% more call options, than puts

Call options by funds: $26.4M | Put options by funds: $6.68M

46% more repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 52

33% more funds holding in top 10

Funds holding in top 10: 6 [Q1] → 8 (+2) [Q2]

14% more capital invested

Capital invested by funds: $451M [Q1] → $516M (+$64.2M) [Q2]

2.46% more ownership

Funds ownership: 93.19% [Q1] → 95.65% (+2.46%) [Q2]

2% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 52

0% more funds holding

Funds holding: 213 [Q1] → 213 (+0) [Q2]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $15
• Avg. target: $16.25
• High target: $18

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Barclays Etzer Darout	$16	Overweight Assumed	17 Sep 2025
HC Wainwright & Co. Andrew S. Fein	$18	Buy Maintained	7 Aug 2025
Wells Fargo Derek Archila	$16	Overweight Maintained	7 Aug 2025
Guggenheim Michael Schmidt	$15	Buy Maintained	7 Aug 2025